AORT
ARTIVION, INC.
$22.35
-1.41%
$1.1B
No data for this timeframe.
Vol
Market Cap$1.1B
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (92%)
Inst. Holders7 funds
Inst. Value$428.4M
Inst. Activity1 buys / 0 sells
Insider Activity0B / 23S
Insider Net $-$4.3M
SEC Reports5
Exchange NYSE·Sector Surgical & Medical Instruments & Apparatus·Inc. DE·CIK 0000784199·Prev Close $22.67
Recent Activity
May 18, 2026
SEC
Artivion completed its acquisition of Endospan Ltd. on May 18, 2026, exercising a long-standing option to purchase all o
8-K — Impact 7/10
May 18, 2026
Insider
Borgstrom Marna P sold 7,576 shares
Director @ $0.00 ($0.00)
May 18, 2026
Insider
SEMEDO ANTHONY B. sold 7,576 shares
Director @ $0.00 ($0.00)
May 18, 2026
Insider
Salveson Jon W sold 7,576 shares
Director @ $0.00 ($0.00)
May 11, 2026
short_volume
Short Volume: AORT — 58.8% short (0.4M / 0.7M)
Short: 434,501 | Exempt: 9,431 | TRF Vol: 738,759 | Short Ratio: 58.8% | Off-exchange volume (dark p
Apr 1, 2026
SEC
Artivion, Inc. (AORT) filed a definitive proxy statement (DEFA14A) related to a shareholder vote. The document appears t
DEFA14A — Impact 3/10
Mar 3, 2026
SEC
Six Artivion executives, including the CEO and CFO, sold shares in a coordinated open-market transaction on March 2, 202
CLUSTER — Impact 7/10
Inst.
WELLS FARGO & COMPANY/MN — ADD
54,398 shares ($2.5M)
Price Targets
$42.00
+87.9% upside
Strong Buy
Current $22.35
Low $36.00
Median $43.00
High $48.00
8 analysts
$36.00
$48.00
Analyst Ratings
5Strong Buy
7Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 8, 2026 | Citizens | MAINTAIN | Market Outperform → Market Outperform |
| May 8, 2026 | Needham | MAINTAIN | Buy → Buy |
| Apr 10, 2026 | Ladenburg Thalmann | UPGRADE | Neutral → Buy |
| Apr 7, 2026 | Needham | REITERATE | Buy → Buy |
| Feb 13, 2026 | Canaccord Genuity | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $0.11 ▼ -47.1% | $0.08 — $0.13 | -54% YoY | 6 |
| Next Q | $0.12 ▼ -44.7% | $0.08 — $0.17 | -26% YoY | 6 |
| Current FY | $0.49 ▼ -39.2% | $0.40 — $0.66 | -22% YoY | 6 |
| Next FY | $0.77 ▼ -33.1% | $0.52 — $1.05 | 57% YoY | 6 |
Latest Reports
BULLISH
8-K
7/10
Artivion completed its acquisition of Endospan Ltd. on May 18, 2026, exercising a long-standing option to purchase all o
May 18, 2026
NEUTRAL
DEFA14A
3/10
Artivion, Inc. (AORT) filed a definitive proxy statement (DEFA14A) related to a shareholder vote. The document appears t
Apr 1, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $144.6M | — |
| FMR LLC | $115.9M | ADD |
| MORGAN STANLEY | $102.9M | — |
| BANK OF AMERICA CORP | $23.7M | — |
| TWO SIGMA INVESTMENTS, LP | $20.2M | DOUBLED |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 18, 2026 | Borgstrom Marna | A | $0.00 |
| May 18, 2026 | SEMEDO ANTHONY | A | $0.00 |
| May 18, 2026 | Salveson Jon | A | $0.00 |
| May 18, 2026 | Burbank Jeffrey | A | $0.00 |
| May 18, 2026 | Bullock James | A | $0.00 |
7 institutional holders with $428.4M total value (9,392,476 shares) as of 2025-Q4. Top holders: VANGUARD, FMR, MORGAN. Net buying activity: 1 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 3,170,089 | $144.6M | 33.8% | — |
| 2 | FMR LLC | 2,541,867 | $115.9M | 27.1% | ADD +30.6% |
| 3 | MORGAN STANLEY | 2,256,742 | $102.9M | 24.0% | — |
| 4 | BANK OF AMERICA CORP /DE/ | 518,535 | $23.7M | 5.5% | — |
| 5 | TWO SIGMA INVESTMENTS, LP | 443,467 | $20.2M | 4.7% | DOUBLED +235.5% |
| 6 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 407,378 | $18.6M | 4.3% | NEW |
| 7 | WELLS FARGO & COMPANY/MN | 54,398 | $2.5M | 0.6% | ADD +78.1% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| WELLS FARGO & COMPANY/MN | ADD | 30,536 | 54,398 | +78.1% | $2.5M | 2025-Q4 |
| FMR LLC | ADD | 2,288,030 | 2,988,161 | +30.6% | $126.5M | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 133,089 | 446,535 | +235.5% | $18.9M | 2025-Q3 |
| UBS Group AG | TRIM | 274,644 | 199,959 | -27.2% | $6.2M | 2025-Q2 |
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 9,340 | 133,089 | +1324.9% | $4.1M | 2025-Q2 |
| FMR LLC | DOUBLED | 1,110,483 | 2,900,842 | +161.2% | $71.3M | 2025-Q1 |
| TWO SIGMA INVESTMENTS, LP | NEW | — | 9,340 | — | $229.6K | 2025-Q1 |
| UBS Group AG | ADD | 186,028 | 241,628 | +29.9% | $6.9M | 2024-Q4 |
| CITADEL ADVISORS LLC | TRIM | 47,190 | 32,200 | -31.8% | $920.6K | 2024-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 349,849 | — | $9.3M | 2024-Q3 |
14 unique insiders with 23 transactions. Net insider value: -$4.3M ($0.00 bought, $4.3M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 18, 2026 | Borgstrom Marna P | Director | A | 7,576 | $0.00 | $0.00 |
| May 18, 2026 | SEMEDO ANTHONY B. | Director | A | 7,576 | $0.00 | $0.00 |
| May 18, 2026 | Salveson Jon W | Director | A | 7,576 | $0.00 | $0.00 |
| May 18, 2026 | Burbank Jeffrey H | Director | A | 7,576 | $0.00 | $0.00 |
| May 18, 2026 | Bullock James | Director | A | 7,576 | $0.00 | $0.00 |
| May 18, 2026 | BEVEVINO DANIEL J | Director | A | 7,576 | $0.00 | $0.00 |
| May 18, 2026 | ACKERMAN THOMAS F | Director | A | 7,576 | $0.00 | $0.00 |
| May 18, 2026 | Hoff Elizabeth A | Director | A | 7,576 | $0.00 | $0.00 |
| May 14, 2026 | Borgstrom Marna P | Director | A | 7,850 | $0.00 | $0.00 |
| Mar 4, 2026 | Holloway Jean F | SVP, General Counsel | SELL | 8,962 | $38.00 | $340.6K |
| Mar 3, 2026 | Holloway Jean F | SVP, General Counsel | SELL | 3,843 | $37.78 | $145.2K |
| Mar 3, 2026 | Davis John E | Chief Commercial Officer | SELL | 4,573 | $37.78 | $172.7K |
| Mar 3, 2026 | Berry Lance A | EVP, COO, CFO & Treasurer | SELL | 6,316 | $37.78 | $238.6K |
| Mar 3, 2026 | Stanton Marshall S. | SVP, Clinical & MD Affair | SELL | 2,149 | $37.78 | $81.2K |
| Mar 2, 2026 | Holloway Jean F | SVP, General Counsel | A | 27,795 | $0.00 | $0.00 |
| Mar 2, 2026 | Horton Amy | VP, Chief Accounting Officer | SELL | 641 | $38.02 | $24.4K |
| Mar 2, 2026 | Davis John E | Chief Commercial Officer | A | 28,845 | $0.00 | $0.00 |
| Mar 2, 2026 | Berry Lance A | EVP, COO, CFO & Treasurer | A | 40,874 | $0.00 | $0.00 |
| Mar 2, 2026 | Mackin James P | President & CEO | SELL | 14,911 | $38.02 | $567.0K |
| Mar 2, 2026 | Berry Lance A | EVP, COO, CFO & Treasurer | SELL | 5,178 | $38.02 | $196.9K |
| Mar 2, 2026 | Davis John E | Chief Commercial Officer | SELL | 2,784 | $38.02 | $105.9K |
| Mar 2, 2026 | Stanton Marshall S. | SVP, Clinical & MD Affair | A | 21,838 | $0.00 | $0.00 |
| Mar 2, 2026 | Stanton Marshall S. | SVP, Clinical & MD Affair | SELL | 1,513 | $38.02 | $57.5K |
| Mar 2, 2026 | Holloway Jean F | SVP, General Counsel | SELL | 2,183 | $38.02 | $83.0K |
| Feb 24, 2026 | Horton Amy | VP, Chief Accounting Officer | SELL | 830 | $35.69 | $29.6K |
| Feb 24, 2026 | Stanton Marshall S. | SVP, Clinical & MD Affair | SELL | 1,259 | $35.69 | $44.9K |
| Feb 24, 2026 | Mackin James P | President & CEO | SELL | 13,936 | $35.69 | $497.4K |
| Feb 24, 2026 | Davis John E | Chief Commercial Officer | SELL | 2,075 | $35.69 | $74.1K |
| Feb 24, 2026 | Holloway Jean F | SVP, General Counsel | SELL | 1,668 | $35.69 | $59.5K |
| Feb 24, 2026 | Berry Lance A | EVP, COO, CFO & Treasurer | SELL | 4,485 | $35.69 | $160.1K |
| Feb 23, 2026 | Horton Amy | VP, Chief Accounting Officer | SELL | 1,731 | $37.59 | $65.1K |
| Feb 23, 2026 | Stanton Marshall S. | SVP, Clinical & MD Affair | SELL | 2,423 | $37.59 | $91.1K |
| Feb 23, 2026 | Berry Lance A | EVP, COO, CFO & Treasurer | SELL | 4,981 | $37.59 | $187.2K |
| Feb 23, 2026 | Holloway Jean F | SVP, General Counsel | SELL | 3,079 | $37.59 | $115.7K |
| Feb 23, 2026 | Mackin James P | President & CEO | SELL | 20,962 | $37.59 | $787.9K |
| Feb 23, 2026 | Davis John E | Chief Commercial Officer | SELL | 3,773 | $37.59 | $141.8K |
5 SEC filing reports analyzed. Sentiment: 1 bullish, 2 bearish, 0 mixed, 2 neutral. Avg impact: 5.6/10.
BULLISH
8-K
7/10
Artivion completed its acquisition of Endospan Ltd. on May 18, 2026, exercising a long-standing opti
May 18, 2026
NEUTRAL
DEFA14A
3/10
Artivion, Inc. (AORT) filed a definitive proxy statement (DEFA14A) related to a shareholder vote. Th
Apr 1, 2026
BEARISH
CLUSTER
7/10
Six Artivion executives, including the CEO and CFO, sold shares in a coordinated open-market transac
Mar 3, 2026
NEUTRAL
CLUSTER
4/10
Artivion's Chief Commercial Officer, Davis John E, sold 2,784 shares in an open-market transaction f
Mar 3, 2026
BEARISH
CLUSTER
7/10
Seven executives at Artivion, Inc. (AORT) sold shares in a concentrated 2-day window, including CEO
Feb 26, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Strong Buy (92% buy). Based on 13 analysts: 5 strong buy, 7 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$42.00 mean target
+87.9% upside
Strong Buy (1.14)
$36.00 Low
$48.00 High
| Metric | Value |
|---|---|
| Current Price | $22.35 |
| Target Low | $36.00 |
| Target Mean | $42.00 |
| Target Median | $43.00 |
| Target High | $48.00 |
| # Analysts | 8 |
| Recommendation | Strong Buy (1.14) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$0.11 | $0.08 | $0.13 | -54.2% | -47.1% | — | $0.1B | 6.3% | 6 |
| Next Q 2026-09-30 |
$0.12 | $0.08 | $0.17 | -26.0% | -44.7% | — | $0.1B | 7.2% | 6 |
| Current FY 2026-12-31 |
$0.49 | $0.40 | $0.66 | -21.7% | -39.2% | 0↑ 1↓ | $0.5B | 10.2% | 6 |
| Next FY 2027-12-31 |
$0.77 | $0.52 | $1.05 | 56.8% | -33.1% | 0↑ 1↓ | $0.5B | 11.0% | 6 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $0.110 | |
| 7d ago | $0.110 | |
| 30d ago | $0.208 | -0.098 |
| 60d ago | $0.208 | -0.098 |
| 90d ago | $0.208 | -0.098 |
4 analyst firms have rated this stock: 1 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 8, 2026 | Citizens | MAINTAIN | Market Outperform | Market Outperform |
| May 8, 2026 | Needham | MAINTAIN | Buy | Buy |
| Apr 10, 2026 | Ladenburg Thalmann | UPGRADE | Neutral | Buy |
| Apr 7, 2026 | Needham | REITERATE | Buy | Buy |
| Feb 13, 2026 | Canaccord Genuity | MAINTAIN | Buy | Buy |
| Feb 2, 2026 | Needham | REITERATE | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| May 1, 2026 | 5 | 7 | 1 | 0 | 0 | 92% | |
| Apr 1, 2026 | 4 | 7 | 2 | 0 | 0 | 85% | |
| Mar 1, 2026 | 4 | 7 | 2 | 0 | 0 | 85% | |
| Feb 1, 2026 | 4 | 7 | 2 | 0 | 0 | 85% | |
| Jan 1, 2026 | 4 | 7 | 2 | 0 | 0 | 85% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 11, 2026
short_volume
Short Volume: AORT — 58.8% short (0.4M / 0.7M)
Short: 434,501 | Exempt: 9,431 | TRF Vol: 738,759 | Short Ratio: 58.8% | Off-exchange volume (dark pool + OTC)
May 7, 2026
earnings_calendar
AORT Q1 2026 Earnings Scheduled — 2026-05-07
Apr 30, 2026
earnings_calendar
AORT Q1 2026 Earnings Scheduled — 2026-04-30
Mar 17, 2026
short_interest
FTD: AORT — 16,174 shares ($0.6M) failed to deliver
Settlement: 20260317, Price: $37.40, FTD Value: $604,907.6, ARTIVION, INC.
Feb 20, 2026
short_interest
FTD: AORT — 85,352 shares ($3.2M) failed to deliver
Settlement: 20260220, Price: $38.00, FTD Value: $3,243,376, ARTIVION, INC.